Prostate cancer risk assessment model: a scoring model based on the Swedish Family-Cancer Database

Roudgari, Hassan; Hemminki, Kari; Brandt, Andreas; Sundquist, Jan; Fallah, Mahdi
May 2012
Journal of Medical Genetics;May2012, Vol. 49 Issue 5, p345
Academic Journal
Background Many prostate cancer (PC) risk assessment models have been developed, however almost none include familial history. Aim To produce a risk assessment model for PC based on familial background of related cancers. Method 976 859 independent index men aged ≥30 in year 1998 and their family members in the Swedish Family-Cancer Database (FCD2010) were randomly divided into development (60%) and validation (40%) datasets (follow-up=10 years). The HR from Cox model was used to extrapolate risk scores. Results Specified scores were: for PC in situ at age <60 years in index man, 5; for PC at age <60 years in each first-degree relative (FDR), 15; for PC at age ≥60 years in each FDR, 10; for PC at age <60 years in each second-degree relative, 5; for breast cancer in each FDR, 2; for oesophageal carcinoma in situ in index man, 2; and for oesophagus cancer in each FDR, 2. Based on the findings, if the milestone age for a PC screening programme was 60 years or more, the recommended starting age for the men with the score-group 6-10 would be 54 years; score-group 11-15, 52 years; score-group 16-20, 50 years; score-group 21-25, 44 years; and or the score-group 26+ it should start before age 40. The concordance index in development and validation sets was 0.885 (95% CI 0.883 to 0.888). No significant difference was found between curves from development and validation datasets (internally validated using twofold validation and bootstrapping). Conclusion Familial history of relevant malignancies can be used as risk factors to estimate a man's prior risk of developing PC. The prostate cancer risk assessment model could satisfactorily assess risk of developing prostate cancer.


Related Articles

  • Risk of cancer in relatives of prostate cancer probands. Isaacs, Sarah D.; Kiemeney, Lambertus A.L.M // JNCI: Journal of the National Cancer Institute;7/5/95, Vol. 87 Issue 13, p991 

    Determines whether hereditary prostate cancer is associated with cancers at other sites and possibly other heritable cancer syndromes. Case-control families; Multiplex families; Poisson regression analysis of relative risks; Cancer occurrence.

  • GENETIC DETERMINANTS OF PROSTATE CANCER: A REVIEW. Kral, Milan; Rosinska, Vlasta; Student, Vladimir; Grepl, Michal; Hrabec, Martin; Bouchal, Jan // Biomedical Papers of the Medical Faculty of Palacky University i;Mar2011, Vol. 155 Issue 1, p3 

    Background. In prostate cancer, early detection and appropriate treatment remain key approaches. But given the constantly increasing incidence, prostate cancer ethiopathogenetic determinants are a current focus of attention. Although the development of this cancer is influenced by both...

  • A urine-based methylation signature for risk stratification within low-risk prostate cancer. Jatkoe, T A; Karnes, R J; Freedland, S J; Wang, Y; Le, A; Baden, J // British Journal of Cancer;3/3/2015, Vol. 112 Issue 5, p802 

    Background:Prostate cancer overdiagnosis and overtreatment represents a major problem. Many men with low-grade disease on biopsy are undergraded and they harbour high-grade disease at prostatectomy with no reliable way to identify these men. We used a novel urine-based 2-gene methylation test to...

  • Can you get prostate cancer from your mom? MARION, MATT // Men's Health;Mar99, Vol. 14 Issue 2, p40 

    Reports on the percentage of hereditary prostate-cancer cases that could be traced to an irregular gene on the X chromosomes which a man inherits from his mother. Comment from research co-director, William Isaacs; Recommendation from the American Cancer Society.

  • GENETICS: Balancing act. Novak, Kristine // Nature Reviews Cancer;Feb2002, Vol. 2 Issue 2, p80 

    Reports that researchers are closing in on a susceptibility target in hereditary prostate cancer (HPC). Findings that mutations in tumor suppressor gene an be linked to (HPC); Loss of heterozygosity in tumor DNA of men from HPC families.

  • You owe your family so much--even your illnesses. Spake, Amanda // U.S. News & World Report;03/12/2001, Vol. 130 Issue 10, p74 

    Discusses the role of family history in disease. Increased health risk, which is dependent on which relatives had the disease; Diseases in which heredity and genetics play a significant role, including cancer, some mental disorders, Alzheimer's disease, and cardiovascular disease; Example of...

  • Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives. Cassidy, A.; Myles, J. P.; Duffy, S. W.; Liloglou, T.; Field, J. K. // British Journal of Cancer;11/6/2006, Vol. 95 Issue 9, p1288 

    To investigate the little known risk of lung cancer at an early age when a first-degree relative has had such a diagnosis, 579 incident cases and 1157 population controls were studied in Liverpool between 1998 and 2004 using standardised questionnaires covering demography and lifestyle. A...

  • Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases. Martinez-Delgado, Beatriz; Yanowsky, Kira; Inglada-Perez, Lucia; de la Hoya, Miguel; Caldes, Trinidad; Vega, Ana; Blanco, Ana; Martin, Teresa; Gonzalez-Sarmiento, Rogelio; Blasco, Maria; Robledo, Mercedes; Urioste, Miguel; Honglin Song; Pharoah, Paul; Benitez, Javier // Journal of Medical Genetics;May2012, Vol. 49 Issue 5, p341 

    Background Alterations in telomere maintenance mechanisms leading to short telomeres underlie different genetic disorders of ageing and cancer predisposition syndromes. It is known that short telomeres and subsequent genomic instability contribute to malignant transformation, and it is therefore...

  • Update on Prostate Cancer Genomics. Srivastava, Abhishek; Gruschow, Siobhan; Tewari, Ashutosh // AUANews;Jan2012, Vol. 17 Issue 1, p12 

    The article focuses on the study of changes in prostate cancer (PC) genome to understand the process of disease initiation, metastasis and progression. It discusses the examination of the biological behavior of early PC to determine the difference of aggressive from indolent disease. It offers...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics